An Introduction to Ovarian Cancer
Before 2016 the prognosis for patients with ovarian cancer was poor, and treatment options were limited. However, the introduction of bevacizumab followed by PARP inhibitors transformed outcomes in patients with BRCA1/2 mutation. Anti-angiogenic agents, immuno-oncology agents, combinations of these agents and hyperthermic intraperitoneal chemotherapy are currently being investigated and show promise for the future.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape.
Ovarian Cancer Content
Keeping pace with the PARP inhibitors: What are the latest data on their role in maintenance treatment for ovarian cancer?
Stay abreast of the latest data for PARP inhibitors in the first-line maintenance treatment of advanced ovarian cancer by watching a webinar and interviews with international experts on data from the virtual SGO and ASCO annual meetings 2020.
- Discuss the use of PARP inhibitor monotherapy in first-line maintenance treatment
- Describe the role of PARP inhibitors in combination first-line maintenance treatment
- Recall the latest safety data for PARP inhibitor maintenance treatment
PARP inhibitor maintenance treatment in advanced ovarian cancer: The who, what and how?
Watch ovarian cancer experts discuss the role of PARP inhibitors in first-line maintenance treatment based on the latest data, as well as which factors influence the choice of PARP inhibitor and the management of possible adverse events.
- Describe the latest data for PARP inhibitors in the first-line maintenance treatment setting
- Discuss approaches to select the most appropriate PARP inhibitor for each patient
- Interpret safety data for PARP inhibitors to help mitigate and manage adverse events
Jonathan A Ledermann – Maintenance Treatment for Recurrent Ovarian Carcinoma
Jonathan A Ledermann (UCL Cancer Institute and University College London Hospitals, London, UK) speaks to us around the topic of the review article he recently co-authored entitled: Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors, which is freely available to access here. Questions 1. For patients with […]
Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors
European Oncology & Haematology. 2019;15(1):29–40 DOI: https://doi.org/10.17925/EOH.2019.15.1.29
Worldwide, ovarian cancer is the seventh most common cancer and the eighth most common cause of cancer death in women.1 The GLOBOCAN study estimated there were 239,000 new cases in 2012 and 152,000 deaths due to this disease. There are nearly 600,000 women living within 5 years of an ovarian cancer diagnosis.1 In the EU, age-adjusted ovarian […]
Advances in the Treatment of Endometrial and Ovarian Cancer
Oncology & Hematology Review. 2019;15(1):23–4 DOI: https://doi.org/10.17925/OHR.2019.15.1.23
Gynecological malignancies can be difficult to treat. Ovarian cancer carries with it the worst prognosis of all gynecological cancers. Approximately 75% of patients with epithelial ovarian cancer are diagnosed with advanced disease which is curable only in a minority of cases, resulting in a 5-year overall survival rate of only 20–30%. However, survival at all […]
Olaparib as a Maintenance Therapy for Ovarian Cancer and its use in BRCA-related Metastatic Breast Cancer
Recent results from trials with olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, are discussed in this Insight. Positive data and regulatory approvals are demonstrating that targeting the underlying genetic causes of a cancer can be a powerful tool for the development of new treatments with efficacy across different cancer types.
Emerging treatments for patients with cancer: practical guidelines and expert insights – An ESMO 2017 Industry Satellite Symposium
Coverage of the satellite symposium session “Emerging treatments for patients with cancer: practical guidelines and expert insights” presented at the European Society for Medical Oncology (ESMO) 2017 Congress on Monday 11 September 2017 in Madrid, Spain. The symposium was supported by Tesaro, who provided this video coverage.
ESMO 2017 – Iain McNeish Interview
Iain McNeish discusses the role of PARP inhibitors, including rucaparib in the treatment of ovarian cancer.
ASCO 2017 – Domenica Lorusso Interview – Part 2
Part 2 of 3 – Dr Domenica Lorusso discusses the ICON 6 trial and the difficulties in analyzing survival benefits in ovarian cancer patients. She also discusses the ANTHALYA study and toxicity of bevacizumab. Speaker disclosures: Advisory Board for Clovis Oncology, Astra Zeneca, PharmaMar, Roche. Filmed at the American Society of Clinical […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!